Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1

References

• Sehouli J, Grabowski JP. Surgery in recurrent ovarian cancer. Cancer. 2019;125(Suppl 24):4598–4601.
   PubMedGoogle Scholar
• Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388(10060):2654–2664.
   PubMed Web of Science ®Google Scholar
• Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28:1767–1775.
   PubMed Web of Science ®Google Scholar
• Lin SR, Chang CH, Hsu CF, et al. Natural compounds as potential adjuvants to cancer therapy: preclinical evidence. Br J Pharmacol. 2020;177:1409–1423.
   PubMed Web of Science ®Google Scholar
• Wang S, Mou J, Cui L, et al. Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3. Biomed Pharmacother. 2018;102:1037–1044.
   PubMed Web of Science ®Google Scholar
• Cai T, Zhang C, Zhao Z, et al. The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats. Biomed Pharmacother. 2018;104:291–299.
   PubMed Web of Science ®Google Scholar
• Wang ZF, Ma DG, Zhu Z, et al. Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts. World J Gastroenterol. 2017;23(48):8512–8525.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wen K. Astragaloside IV inhibits TGF-beta1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-kappaB pathway in gastric cancer cells. Phytother Res. 2018;32:1289–1296.
   PubMed Web of Science ®Google Scholar
• Ye Q, Su L, Chen D, et al. Astragaloside IV induced miR-134 expression reduces EMT and increases chemotherapeutic sensitivity by suppressing CREB1 signaling in colorectal cancer cell line SW-480. Cell Physiol Biochem. 2017;43:1617–1626.
   PubMedGoogle Scholar
• Zou J, Liao X, Zhang J, et al. Dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer. J Biol Regul Homeost Agents. 2019;33:1377–1385.
   PubMed Web of Science ®Google Scholar
• Liu F, Qiu F, Fu M, et al. Propofol reduces epithelial to mesenchymal transition, invasion and migration of gastric cancer cells through the MicroRNA-195-5p/Snail Axis. Med Sci Monit. 2020;26:e920981.
   PubMed Web of Science ®Google Scholar
• Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20:5–20.
   PubMed Web of Science ®Google Scholar
• Li J, Chen L, Xiong Y, et al. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem. 2017;41:907–920.
   PubMedGoogle Scholar
• He PX, Ma ZL, Han H, et al. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer. Life Sci. 2020;242:117247.
   PubMed Web of Science ®Google Scholar
• Zhou WY, Zhang MM, Liu C, et al. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p. J Cell Physiol. 2019;234:23176–23189.
   PubMed Web of Science ®Google Scholar
• Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep. 2013;40(3):2091–2096.
   PubMed Web of Science ®Google Scholar
• You W, Liu X, Yu Y, et al. miR-502-5p affects gastric cancer progression by targeting PD-L1. Cancer Cell Int. 2020;20:395.
   PubMed Web of Science ®Google Scholar
• Hu YY, Zhao YM, Zhang X, et al. Rebound adenotonsillar and thymic uptake of 18F-FDG in paediatric patients with lymphoma. Eur J Radiol. 2020;133:109348.
   PubMed Web of Science ®Google Scholar
• OuYang Y, Huang J, OuYang Z, et al. Enrichment and purification process of astragalosides and their anti-human gastric cancer MKN-74 cell proliferation effect. Afr Health Sci. 2014;14:22–27.
   PubMed Web of Science ®Google Scholar
• Jiang K, Lu Q, Li Q, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2017;42:195–202.
   PubMed Web of Science ®Google Scholar
• Su CM, Wang HC, Hsu FT, et al. Astragaloside IV induces apoptosis, G1-phase arrest and inhibits anti-apoptotic signaling in hepatocellular carcinoma. In Vivo. 2020;34:631–638.
   PubMed Web of Science ®Google Scholar
• Jia L, Lv D, Zhang S, et al. Astragaloside IV inhibits the progression of non-small cell lung cancer through the Akt/GSK-3beta/beta-catenin pathway. Oncol Res. 2019;27:503–508.
   PubMed Web of Science ®Google Scholar
• Sun P, Liu Y, Wang Q, et al. Astragaloside IV inhibits human colorectal cancer cell growth. Front Biosci. 2019;24:597–606.
   Web of Science ®Google Scholar
• Zhang L, Zhou J, Qin X, et al. Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGFbeta1mediated PI3K and MAPK pathways. Oncol Rep. 2019;41:2975–2986.
   PubMed Web of Science ®Google Scholar
• Li Y, Ye Y, Chen H. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB. Biomed Pharmacother. 2018;99:134–141.
   PubMed Web of Science ®Google Scholar
• Han J, Shen X, Zhang Y, et al. Astragaloside IV suppresses transforming growth factor-beta1-induced epithelial-mesenchymal transition through inhibition of Wnt/beta-catenin pathway in glioma U251 cells. Biosci Biotechnol Biochem. 2020;84:1345–1352.
   PubMed Web of Science ®Google Scholar
• Qin CD, Ma DN, Ren ZG, et al. Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3beta/beta-catenin pathway. Oncol Rep. 2017;37:1725–1735.
   PubMed Web of Science ®Google Scholar
• Xu F, Cui WQ, Wei Y, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res. 2018;37(1):207.
   PubMed Web of Science ®Google Scholar
• Lin X, Wang S, Sun M, et al. Correction to: miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization. J Hematol Oncol. 2019;12:122.
   PubMed Web of Science ®Google Scholar
• Zhao DL, Wu QL. Effect of inhibition to Yes-related proteins-mediated Wnt/beta-catenin signaling pathway through miR-195-5p on apoptosis of gastric cancer cells. Eur Rev Med Pharmacol Sci. 2019;23:6486–6496.
   PubMed Web of Science ®Google Scholar
• Wang J, Li L, Jiang M, et al. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor. Clin Transl Oncol. 2017;19:1320–1328.
   PubMed Web of Science ®Google Scholar
• Tran PN, Sarkissian S, Chao J, et al. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointest Cancer. 2017;7:1–11.
   PubMedGoogle Scholar
• Amatatsu M, Arigami T, Uenosono Y, et al. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. Cancer Sci. 2018;109(3):814–820.
   PubMed Web of Science ®Google Scholar
• Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901–909.
   PubMed Web of Science ®Google Scholar
• Saito H, Kono Y, Murakami Y, et al. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer Res. 2018;38:107–112.
   PubMed Web of Science ®Google Scholar
• Zhang L, Qiu M, Jin Y, et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol. 2015;8:11084–11091.
   PubMed Web of Science ®Google Scholar
• Mu L, Yu W, Su H, et al. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. Artif Cells Nanomed Biotechnol. 2019;47:1036–1042.
   PubMed Web of Science ®Google Scholar
• Zhang C, Cai T, Zeng X, et al. Astragaloside IV reverses MNNG-induced precancerous lesions of gastric carcinoma in rats: regulation on glycolysis through miRNA-34a/LDHA pathway. Phytother Res. 2018;32:1364–1372.
   PubMed Web of Science ®Google Scholar
• Cui X, Jiang X, Wei C, et al. Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/beta-catenin axis. Environ Toxicol Pharmacol. 2020;78:103397.
   PubMed Web of Science ®Google Scholar